112 related articles for article (PubMed ID: 33497993)
1. Corrigendum to 'Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study': [ESMO Open Volume 5, Issue 6, 2020, e000985].
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2021 Feb; 6(1):100052. PubMed ID: 33497993
[No Abstract] [Full Text] [Related]
2. Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].
Sinn K; Mosleh B; Steindl A; Zoechbauer-Mueller S; Dieckmann K; Widder J; Steiner E; Klepetko W; Hoetzenecker K; Laszlo V; Dome B; Klikovits T; Hoda MA
ESMO Open; 2022 Jun; 7(3):100523. PubMed ID: 35696745
[No Abstract] [Full Text] [Related]
3. Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].
Hotta K; Saeki S; Yamaguchi M; Harada D; Bessho A; Tanaka K; Inoue K; Gemba K; Shiojiri M; Kato Y; Ninomiya T; Kubo T; Kishimoto J; Shioyama Y; Katsui K; Sasaki J; Kiura K; Sugio K
ESMO Open; 2022 Aug; 7(4):100532. PubMed ID: 35802950
[No Abstract] [Full Text] [Related]
4. Corrigendum to 'Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States': [ESMO Open Volume 6, Issue 5, October 2021, 100252].
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Dec; 6(6):100286. PubMed ID: 34678570
[No Abstract] 
